A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

Published:2015-10 Issue:10 Volume:26 Page:2066-2072
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yoshioka H.,Azuma K.,Yamamoto N.,Takahashi T.,Nishio M.,Katakami N.,Ahn M.J.,Hirashima T.,Maemondo M.,Kim S.W.,Kurosaki M.,Akinaga S.,Park K.,Tsai C.M.,Tamura T.,Mitsudomi T.,Nakagawa K.

Funder

Kyowa Hakko Kirin, Co., Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/10/2066/16703052/mdv288.pdf

Reference21 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Management of non-small-cell lung cancer: recent developments;Reck;Lancet,2013

3. Non-small cell lung cancer;Ettinger;J Natl Compr Canc Netw,2010